Research and Development, Sanofi Pasteur, 69007 Lyon, France.
Cold Spring Harb Perspect Biol. 2018 Jun 1;10(6):a029462. doi: 10.1101/cshperspect.a029462.
Dengue is a still-growing public health concern in many tropical and subtropical regions of the world. The development and implementation of an effective dengue vaccine in these regions is a high priority. This insight focuses on the expected characteristics of a safe and efficacious vaccine, referring to the clinical experience obtained during the development of the first tetravalent dengue vaccine from Sanofi Pasteur, now licensed in several endemic countries. Safety and efficacy data from both short- and long-term follow-up of large-scale efficacy studies will be discussed, as well as the next steps following vaccine introduction.
登革热仍然是世界上许多热带和亚热带地区日益严重的公共卫生关注点。在这些地区开发和实施有效的登革热疫苗是当务之急。本观点重点介绍安全有效的疫苗的预期特征，同时提到赛诺菲巴斯德开发的首个四价登革热疫苗的临床经验，该疫苗现已在几个流行国家获得许可。将讨论来自大规模疗效研究的短期和长期随访的安全性和疗效数据，以及疫苗推出后的下一步措施。
